Don't give sildenafil to children, FDA warns
Children aged between 1 and 17 years should not take sildenafil for pulmonary artery hypertension, a MedWatch safety communication from the US Food and Drug Administration (FDA) warns. More >>
Children aged between 1 and 17 years should not take sildenafil for pulmonary artery hypertension, a MedWatch safety communication from the US Food and Drug Administration (FDA) warns.
FDA based its recommendation on a long-term pediatric clinical trial that found a greater risk of death among children who took a high dose of sildenafil than for children who took a low dose. Low doses of the drug did not improve exercise ability in treated children.
Sildenafil is approved to enhance exercise ability in adults with pulmonary artery hypertension and slow the progression of the condition by relaxing the blood vessels in the lungs and lowering blood pressure. Treatment of pediatric pulmonary artery hypertension with sildenafil is an off-label use.
FDA has added a new warning to the drug’s labeling stating that sildenafil is not recommended for pediatric patients. Caregivers of children taking the drug should consult a health care professional before discontinuing it or changing the dose.
Go back to the current issue of the eConsult.
Pediatric patients with uveitis at elevated risk of cataracts, study finds
July 24th 2024Risk for cataract development was assessed at specific follow-up durations of 1 year, 2 years, 5 years, and 20 years following the index date, with an increased risk of cataracts development among patients aged younger than 18 years present at each time point.
Comparison of teen- and parent-reported estimates of social and emotional support, 2021 to 2022
July 23rd 2024The investigative team noted that teenagers with emotional and social support are better off to handle stressors such as biological and social transition, and are less likely to experience a variety of adverse physical and mental health outcomes.
